Phase II study of azacitidine to restore responsiveness of prostate cancer to hormonal therapy |
| |
Authors: | Sonpavde Guru Aparicio Ana Guttierez Israel Boehm Kristi A Hutson Thomas E Berry William R Asmar Lina von Hoff Daniel D |
| |
Institution: | US Oncology Research, Inc., 501 Medical Center Blvd, Webster, TX 77598, USA. guru.sonpavde@usoncology.com |
| |
Abstract: | Epigenetic alterations, including methylation of key tumor suppressor genes, may play a role in the progression of prostate cancer to a castration-refractory state. Azacitidine, an agent approved for the treatment of myelodysplastic syndromes, appears to exert its antineoplastic effects partly by hypomethylating DNA that leads to the reversal of gene silencing. It is hypothesized that the addition of azacitidine to complete androgen blockade may restore the responsiveness of progressive prostate cancer to hormonal therapy. A phase II trial was designed to evaluate the activity of azacitidine to primarily modulate PSA kinetics, with supportive secondary clinical endpoints. Correlative studies will be performed to detect the biologic activity of azacitidine (increased fetal hemoglobin, plasma DNA methylation) and examine any association with anti-tumor clinical activity. |
| |
Keywords: | Androgen-deprivation therapy Myelodysplastic syndrome Prostatespecific antigen |
本文献已被 ScienceDirect PubMed 等数据库收录! |
|